Buspirone Market Trends, Share & Demand by 2034

Coverage: By Product (5mg, 10mg, 15mg, 30mg); Application (Anxiety, Psychosis, Others); End User (Hospitals, Clinics, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00019745
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : April 28, 2026
Buspirone Market Trends, Share & Demand by 2034
Report Date: April 28, 2026   |   Report Code: TIPRE00019745 Email: sales@theinsightpartners.com

2025 Market Size

US$ 11.96 Bn

Base year value

2034 Forecast

US$ 24.27 Bn

Projected by 2034

CAGR 2026-2034

8.18 %

Growth rate

Addressable Market

US$ 162.79 Bn

(2026-2034)

The Buspirone Market size is expected to reach US$ 24.27 Billion by 2034 from US$ 11.96 Billion in 2025. The market is estimated to record a CAGR of 8.18% from 2026 to 2034.

The Buspirone Market report covers analysis by Product (5mg, 10mg, 15mg, 30mg); Application (Anxiety, Psychosis, Others); End User (Hospitals, Clinics, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.

Purpose of the Report

The report Buspirone Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Buspirone Market Segmentation

Product

  1. 5mg
  2. 10mg
  3. 15mg
  4. 30mg

Application

  1. Anxiety
  2. Psychosis

End User

  1. Hospitals
  2. Clinics

Market Research Highlights

  • Global market for Buspirone was valued at US$ 11.96 Billion in 2025
  • Annual market size is expected to reach US$ 24.27 Billion by 2034
  • Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 162.79 Billion
  • Market is anticipated to register a CAGR of 8.18% during the forecast period
  • The United States represents a key market, supported by Rising Incidences of Anxiety Disorders, Increasing Usage of Non-Benzodiazepine Hypnotics, Added Mental Health Awareness, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Progress in Digital Platforms for Mental Health, Combination Therapy Potential, Increasing Attention Paid by Organizations to Mental Health are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Bristol Myers Squibb, Apotex, Dr. Reddy's Laboratories, Laboratoires Servier, Teva, AMAG Pharmaceuticals, Mylan, Novartis, Hikma, while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Buspirone Market: Strategic Insights

buspirone-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Buspirone Market Growth Drivers

  1. Rising Incidences of Anxiety Disorders: The increasing incidence of anxiety disorders, such as generalized anxiety disorder (GAD), stands as the major factor propelling the market for buspirone. Buspirone non-benzodiazepine anxiolytic agent is generally advised for symptom management of anxiety with fewer chances of substance dependence when used, in comparison with other anti-anxiety medications. Therefore, as the burden of mental health disorders increases, the demand for treatments like buspirone will, thus, rise.
  2. Increasing Usage of Non-Benzodiazepine Hypnotics: Increasingly more patients and healthcare givers have shown preference for non-benzodiazepine medications due to high prospects of addiction and side effects from taking benzodiazepines. Buspirone is then chosen since it is less dependent than most and has no side effects of sedation making it a good alternative in the treatment of anxiety without the risks caused by other anxiolytics.
  3. Added Mental Health Awareness: The increased awareness regarding mental health issues and the need for seeking professional healing therapies thereby creates the market for drugs like buspirone. Health awareness campaigns and mass media will motivate people to visit health facilities to get help in cases of anxiety as well as stress leading to an increased amount of prescriptions for medications such as buciprone to treat these conditions.

Buspirone Market Future Trends

  1. Growing Trend Toward Personalized Medicine: These factors have started to influence the buspirone market in terms of personalized medicine because treatment will no longer be directed toward a patient only based on the patient's unique genetics, environment, and lifestyle factors, but it will also select the most effective and safe medications for managing anxiety. Thus, the application of drugs such as buspirone that has a safe profile becomes quite popular as it enhances its demand.
  2. Increase in Online and Telehealth Consultations: There has been an incremental adoption of telehealth and online consultations. This is also one of the contributing factors to the growing buspirone market. While many people are looking for medical advice via telemedicine, the prescription of the anxiolytic drug buspirone is likely becoming more prevalent. This sort of platform enables easy access to mental health services and, as such, drives the buspirone market.
  3. Focus on Non-Pharmacologic Treatment of Anxiety: Popular medications, such as buspirone, are trending toward using behavioral therapies, such as CBAn, meditation, and mindfulness practices. The trend is opening the way for greater integration of buspirone treatment into the broader holistic treatment plan for anxiety, as behavior therapy with buspirone improves outcomes for patients.

Buspirone Market Opportunities

  1. Progress in Digital Platforms for Mental Health: The progressive proliferation of digital platforms and applications for treating anxiety has paved the way for buspirone. These platforms offer self-guided tools and therapeutic interventions, occasionally employed with medications such as buspirone. Through digital health partnerships, buspirone would gain further visibility and market penetration, especially among tech-savvy communities.
  2. Combination Therapy Potential: Combining buspirone with other drugs, like antidepressants or mood stabilizers, has a prospective opportunity to expand its therapeutic effect. "Combination therapy" seems to be gaining momentum toward a comprehensive approach to treating anxiety and related disorders. It would also mean more patient convenience and market potential for buspirone through the creation of combination products.
  3. Increasing Attention Paid by Organizations to Mental Health: As these organizations pay more emphasis to mental health and welfare in the workplace, buspirone can be included in employee health programs. Such organizations may just offer access to medications like buspirone to employees who deal with the effects of stress, anxiety, and other mental health challenges. That will translate into demand for buspirone as part of the employee wellness initiative.

Buspirone Market Report Scope

Report Attribute Details
Market size in 2025 US$ 11.96 Billion
Market Size by 2034 US$ 24.27 Billion
Global CAGR (2026 - 2034) 8.18%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Product
  • 5mg
  • 10mg
  • 15mg
  • 30mg
By Application
  • Anxiety
  • Psychosis
By End User
  • Hospitals
  • Clinics
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Bristol Myers Squibb
  • Apotex
  • Dr. Reddy's Laboratories
  • Laboratoires Servier
  • Teva
  • AMAG Pharmaceuticals
  • Mylan
  • Novartis
  • Hikma

Buspirone Market Players Density: Understanding Its Impact on Business Dynamics

The Buspirone Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

buspirone-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Buspirone Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Buspirone Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

The major factors driving the Buspirone Market are Rising Incidences of Anxiety Disorders, Increasing Usage of Non-Benzodiazepine Hypnotics, and Added Mental Health Awareness

The key future trends of the market are Growing Trend Toward Personalized Medicine, Increase in Online and Telehealth Consultations, and Focus on Non-Pharmacologic Treatment of Anxiety

The leading players operating in the Buspirone Market include Bristol Myers Squibb, Apotex, Dr. Reddy's Laboratories, Laboratoires Servier, Teva, AMAG Pharmaceuticals, Mylan, Novartis, Hikma

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Some of the customization options available based on the request are an additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA